The molecular landscape of melanoma brain metastases

SUPR uses JavaScript for certain functions. We cannot guarantee that you will be able to use the system with JavaScript disabled.

Dnr:

sens2023571

Type:

NAISS SENS

Principal Investigator:

Hanna Eriksson

Affiliation:

Karolinska Institutet

Start Date:

2023-08-18

End Date:

2024-09-01

Primary Classification:

30203: Cancer and Oncology

Webpage:

https://ki.se/en/onkpat/hanna-erikssons-group

Allocation

Castor /proj at UPPMAX: 1000 GiB
Castor /proj/nobackup at UPPMAX: 1000 GiB
Cygnus /proj at UPPMAX: 1000 GiB
Cygnus /proj/nobackup at UPPMAX: 1000 GiB
Bianca at UPPMAX: 2 x 1000 core-h/month

Abstract

Patients with melanoma brain metastases (MBM) have poor survival and limited effect of immune-based threapies. We have matched samples from MBM patients including tissue and plasma for analyses that include RNAseq, spatial transcriptimics and proteomics to investigate the molecular landscape in MBM.